Results 51 to 60 of about 15,231 (118)

Multivalent Atezolizumab-Liposome Conjugates as Active Immunotherapeutic Platforms for Enhanced PD-L1 Blockade in Melanoma. [PDF]

open access: yesInt J Nanomedicine
Cheng Z   +7 more
europepmc   +1 more source

Immunoexpression of programmed death receptor 1 and its ligands in oral cavity squamous cell carcinoma. [PDF]

open access: yesMed Oral Patol Oral Cir Bucal
Anjos RS   +5 more
europepmc   +1 more source

Ipilimumab, -omics, and head and neck cancers-update in 2025. [PDF]

open access: yesFront Immunol
Kucharski R   +3 more
europepmc   +1 more source

A novel TM4SF4-targeting therapeutic antibody candidate with antitumor activity by blocking IGF1R and CD44 signaling and downregulating PD-L1 and B7-H4. [PDF]

open access: yesTheranostics
Kim RK   +14 more
europepmc   +1 more source

Regulation and Mechanism of Deleted in Breast Cancer-1 on Dendritic Cell Function in Systemic Lupus Erythematosus. [PDF]

open access: yesMedComm (2020)
Xiao ZX   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy